|
Tabla 3: Comparación con otros estudios de validación de WINROP. |
|||||||
|
Autor |
Año |
País |
No. de Pacientes |
Sensibilidad (%) |
Especificidad (%) |
VPP (%) |
VPN (%) |
|
Hellstrom et al.6 |
2009 |
Suecia |
353 |
100 |
85 |
41 |
NR |
|
Wu et al.7 |
2010 |
EE. UU. |
318 |
100 |
82 |
34.6 |
100 |
|
Hård et al.8 |
2010 |
Brasil |
366 |
91 |
55 |
10 |
99 |
|
Wu et al.9 |
2012 |
EE. UU., Canadá |
1,706 |
99 |
36 |
13.1 |
99.7 |
|
Zepeda-Romero et al.10 |
2012 |
México |
352 |
55 |
27 |
NR |
NR |
|
Sun et al.11 |
2013 |
China |
590 |
89 |
89 |
45.9 |
98.8 |
|
Choi et al.12 |
2013 |
Corea del Sur |
314 |
90 |
53 |
21.7 |
97.3 |
|
Lundgren et al.13 |
2013 |
Suecia |
407 |
96 |
24 |
14.1 |
97.7 |
|
Piyasena et al. 14 |
2014 |
Reino Unido |
410 |
88 |
63 |
8.8 |
99.2 |
|
Eriksson et al. 15 |
2014 |
Suecia |
104 |
100 |
59 |
10.8 |
100 |
|
Ko et al.16 |
2015 |
Taiwán |
148 |
65 |
55 |
15.7 |
92.3 |
|
Koçak et al.17 |
2016 |
Turquía |
223 |
84 |
53 |
23 |
95.2 |
|
Piermarocchi et al. 18 |
2017 |
Italia |
377 |
84 |
55 |
NR |
NR |
|
Jagla et al.19 |
2017 |
Polonia |
79 |
82 |
71 |
59.5 |
88.1 |
|
Sanghi et al.20 |
2018 |
India |
70 |
90 |
38 |
53.8 |
83.3 |
|
Di Lim et al.21 |
2020 |
Malasia |
92 |
95 |
38 |
29.9 |
96.0 |
|
Estudio actual |
2022 |
México |
77 |
96 |
84 |
92.5 |
91.0 |
|
VPP = valor predictivo positivo. VPN = valor predictivo negativo. NR = no se reporta. |
|||||||